Combining the power of DNA-encoded libraries with rational, computer assisted drug design to discover novel therapeutics for difficult to treat diseases.
X-Rx is a discovery-stage company with the capabilities and know-how to discover and develop first- and best-in-class small molecule medicines in a manner that is rapid, cost-effective and high quality.
Co-founded in 2012 by PPD as majority owner and X-Chem, X-Rx is a biotech company with more than 80 years of combined drug discovery and development experience. The portfolio includes targets across a number of families with multiple series of chemical starting points.
The X-Rx Advantage
X-Rx holds a collection of high-value targets coupled with access to DNA-encoded libraries and strong competencies in structure-based drug design. X-Rx has the ability to quickly identify tractable lead series on a wide range of targets.
The X-Rx Pipeline
X-Rx has multiple leads at discovery phase in the following target areas: protein-protein interactions, epigenetics, kinases, ligases and GPCRs as well as access to new screens for novel targets.
X-Rx Announces Autotaxin Inhibitor Collaboration with Gilead Sciences
On November 11, 2015, X-Rx, Inc. announced that it has entered into an exclusive agreement with Gilead Sciences, Inc. to develop X-Rx’s proprietary small molecule autotaxin (ATX) inhibitors. ATX plays a key role in maintaining tissue homeostasis and is upregulated in many diseases, including idiopathic pulmonary fibrosis (IPF). Inhibition of ATX leads to a reduction in lysophosphatidic acid production, which blocks signaling cascades that ultimately drive the development of fibrosis.